Terpenoid derivatives

Patent metadata

Field	Value
Publication number	US-9796752-B2
Application number	US-201414778006-A
Country	US
Kind code	B2
Filing date	Mar 18, 2014
Priority date	Mar 19, 2013
Publication date	Oct 24, 2017
Grant date	Oct 24, 2017

Abstract

It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway. The present invention provides terpenoid derivative A represented by the following formula (I):

First claim

The invention claimed is:

1. A terpenoid derivative represented by the following formula (II):

2. A method for producing a compound according to claim 1 , comprising using a compound represented by the following formula (VIII):

as a substrate, culturing this compound in a medium together with a strain for transformation of the genus Chaetomium capable of transforming the compound to the compound according to claim 1 , and collecting the compound according to claim 1 from the cultures.

3. The method for producing a compound according to claim 2 , wherein the strain for transformation is a Chaetomium globosum SANK 10312 strain (Deposition No. NITE BP-1486) belonging to the genus Chaetomium.

4. A method for producing a compound according to claim 1 , comprising using a compound represented by the following formula (VIII):

as a substrate, culturing this compound in a medium together with a strain for transformation of the genus Mucor capable of transforming the compound to the compound according to claim 1 , and collecting the compound according to claim 1 from the cultures.

5. The method for producing a compound according to claim 4 , wherein the strain for transformation is a Mucor hiemalis f hiemalis SANK 10612 strain (Deposition No. NITE BP-1488) belonging to the genus Mucor.

6. A medicament comprising a terpenoid derivative according to claim 1 as an active ingredient.

Assignees

• Daiichi Sankyo Co Ltd

Inventors

• Komoriya Satoshi
• Nakagami Yasuhiro
• Hatano Emiko
• Ohnuki Takashi
• Masuda Kayoko
• Iizuka Mayumi
• Ono Yasunori

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P27/14

  Decongestants or antiallergics · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title